Clinical spectrum of chronic acquired demyelinating polyneuropathies

Muscle and Nerve

Volumn 24, Issue 3, 2001, Pages 311-324

  Saperstein, David S ^a   Katz, Jonathan S ^b   Amato, Anthony A ^c   Barohn, Richard J ^d  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic inflammatory demyelinating polyneuropathy (CIDP); Distal acquired demyelinating symmetric (DADS) neuropathy; Lewis Sumner syndrome; Multifocal acquired demyelinating sensory and motor (MADSAM) neuropathy; Multifocal motor neuropathy (MMN)

Indexed keywords

CHRONIC INFLAMMATION; CLINICAL FEATURE; CLINICAL PRACTICE; DEMYELINATING NEUROPATHY; DIAGNOSTIC APPROACH ROUTE; HUMAN; MOTOR NEUROPATHY; MUSCLE WEAKNESS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY;

HUMANS; POLYNEUROPATHIES; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 0035111287     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-4598(200103)24:3<311::AID-MUS1001>3.0.CO;2-A     Document Type: Review

References (142)

1. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force
2. Polyneuropathy complicating bone marrow transplantation
3. Chronic relapsing brachial plexus neuropathy with persistent conduction block
4. Neuropathy with onion bulb formations and pure motor manifestations
5. Recurrent polyneuropathies and their corticosteroid treatment
6. Effect of cyclophosphamide in multifocal motor neuropathies with or without conduction block
7. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: A double-blind, placebo-controlled study
8. Long term follow up of multifocal motor neuropathy with conduction block under treatment
9. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria
10. Guillain-Barrésyndrome and chronic inflammatory demyelinating polyneuropathy
11. Late motor involvement in cases presenting as "chronic sensory demyelinating polyneuropathy"
12. Multifocal motor neuropathy
13. Anti-MAG antibody-associated polyneuropathies: Improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide
14. Disorders of peripheral nerves
15. Chronic inflammatory demyelinating polyneuropathy
16. Comparison of electrodiagnostic criteria for primary demyelination in chronic polyneuropathy
17. Marginally improved detection of GM1 antibodies by Covalink ELISA in multifocal motor neuropathy
18. Deterioration of multifocal motor neuropathy after plasma exchange
19. Slow resolution of multifocal weakness and fasciculation: A reversible motor neuron syndrome
20. Intravenous immunoglobulin treatment in multifocal motor neuropathy
21. Peripheral neuropathy associated with IgM monoclonal gammopathy: Correlations between M-protein antibody activity and clinical/electrophysiological features in 40 cases
22. Multifocal motor neuropathy
23. Maintenance immune globulin therapy for multifocal motor neuropathy: Results of long-term follow-up
24. Multifocal motor neuropathy: Response to human immune globulin
25. Multifocal motor neuropathy: Electrodiagnostic features
26. Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy
27. Chronic relapsing axonal neuropathy: A first case report
28. Clinical and neurophysiological assessment of immunoglobulin therapy in five patients with multifocal motor neuropathy
29. Conduction block in clinical practice
30. Electrophysiological improvement after intravenous immunoglobulin in motor neuropathy with multifocal conduction block
31. Tremor as a feature of chronic relapsing and dysgammaglobulinemic polyneuropathies. Incidence and management
32. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy
33. Clinical features and anti-neural reactivity in neuropathy with IgG monoclonal gammopathy of undetermined significance
34. Pure motor demyelinating neuropathy: Deterioration after steroid treatment and improvement with intravenous immunoglobulin
35. Chronic progressive axonal polyneuropathy simulating Guillain-Barré syndrome
36. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy
37. Chronic inflammatory polyradiculoneuropathy
38. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy
39. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance
40. Prednisone improves chronic inflammatory, demyelinating polyradiculoneuropathy more than no treatment
41. Neuropathy associated with "benign" anti-myelin-associated glycoprotein IgM gammopathy: Clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases
42. Use of human intravenous immunoglobulin in lower motor neuron syndromes
43. Peripheral neuropathy and monoclonal IgM with antibody activity against peripheral nerve myelin; effect of plasma exchange
44. Axonal CIDP: A premature concept?
45. Immunosuppressive treatment in multifocal motor neuropathy
46. Chronic multifocal neuropathy with persistent conduction block (Lewis-Sumner syndrome). A clinico-morphologic study of two further cases with review of the literature
47. Chronic inflammatory demyelinating polyneuropathy: Clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy
48. Improvement following interferon-alpha 2A in chronic inflammatory de myelinating polyneuropathy
49. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a
50. Upper limb predominant, multifocal chronic inflammatory demyelinating polyneuropathy
51. Neuropathy associated with monoclonal gammopathies of undetermined significance
52. Sur un syndrome de radicu lonévrite avec hyperalbuminose du liquide céphalorachidien sans réaction cellulaire. Remarques sur les caractéres cliniques et graphiques de réflexes tendineux
53. Plasmapheresis alleviates neuropathy accompanying IgM anti-myelin-associated glycoprotein para proteinemia
54. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: A double-blind, sham-controlled, cross-over study
55. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, cross-over study
56. Clinical improvement following interferon-alpha alone as an initial treatment in CIDP
57. Subacute idiopathic demyelinating polyradiculoneuropathy
58. Chronic relapsing idiopathic polyneuropathy with primary axonal lesions
59. Anti-GM1 antibodies and impaired blood-nerve barrier may interfere with remyelination in multifocal motor neuropathy
60. Multifocal demyelinating motor neuropathy: Cranial nerve involvement and immunoglobulin therapy
61. Distal accentuation of conduction slowing in polyneuropathy associated with anti-bodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside
62. Chronic relapsing axonal neuropathy responsive to intravenous immunoglobulin
63. Distal acquired demyelinating symmetrical neuropathy
64. Electrophysiologic findings in multifocal motor neuropathy
65. Polyneuropathies associated with IgM monoclonal gammopathies
66. Clinical and electrophysiologic correlates of elevated anti-GM1 antibody titers
67. Neuropathies associated with monoclonal proteins
68. The clinical and diagnostic role of anti-GM1 antibody testing
69. A syndrome of asymmetric limb weakness with motor conduction block
70. Interferonbetala in chronic inflammatory demyelinating polyneuropathy
71. Neuropathy associated with the monoclonal gammopathies
72. Multifocal motor neuropathy with conduction block: Is it a distinct clinical entity?
73. Peripheral neuropathy and anti-MAG antibodies
74. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab
75. Multifocal motor neuropathy and Lewis-Sumner syndrome: Two distinct entities
76. Multifocal demyelinating neuropathy with persistent conduction block
77. A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Poly neuropathy Study Group
78. A randomized double-blind trial versus placebo does not confirm the efficacy of alpha-interferon in polyneuropathy associated with anti-MAG IgM monoclonal gammopathy
79. Response to therapy in demyelinating motor neuropathy
80. Chronic motor neuropathies: Response to interferon-betala after failure of conventional therapies
81. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases
82. Chronic inflammatory demyelinating polyneuropathy
83. Intravenous immunoglobulin in untreated patients with chronic inflammatory demyelinating polyneuropathy
84. Plasma exchange and prednisone in Guillain-Barré syndrome: A controlled randomized trial
85. Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy
86. Another case of chronic relapsing axonal neuropathy
87. Multifocal motor and sensory demyelinating neuropathy (MMSDN): A probable distinct condition from multifocal motor neuropathy (MMN)
88. Treatment of patients with neuropathy and anti-MAG IgM M-proteins
89. Neuropathy and anti-MAG antibodies without detectable serum M-protein
90. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy
91. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies
92. Multifocal motor neuropathy: Comparison of clinical and immunological features and response to IVIg in patients with and without overt conduction block
93. Diagnostic criteria for demyelinating polyneuropathy associated with monoclonal gammopathy
94. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance
95. Is ischemia implicated in chronic multifocal demyelinating neuropathy?
96. Subacute demyelinating polyneuropathy responding to corticosteroid treatment
97. Motor and sensory demyelinating mononeuropathy multiplex (multifocal motor and sensory demyelinating neuropathy): A separate variant of chronic inflammatory demyelinating polyneuropathy
98. "Chronic sensory demyelinating neuropathy": Chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy
99. A case of chronic sensory demyelinating neuropathy responding to immunotherapies
100. What is the best diagnostic index of conduction block and temporal dispersion
101. Consensus criteria for the diagnosis of partial conduction block
102. Prednisone treatment of multifocal motor neuropathy
103. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy
104. Multifocal motor neuropathy without overt conduction block
105. Antiganglioside antibodies do not necessarily play a role in multifocal motor neuropathy
106. Are multifocal motor neuropathy and Lewis-Sumner syndrome distinct nosologic entities?
107. Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease
108. Multifocal motor neuropathy
109. Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies
110. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates
111. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside
112. Neurology and the bone marrow
113. Long-term clinical and neurophysiological follow-up of patients with peripheral neuropathy associated benign monoclonal gammopathy
114. Chronic demyelinating polyneuropathy in systemic lupus erythematosus
115. A computer simulation of conduction block: Effects produced by actual block versus interphase cancellation
116. Extraneural manifestations of chronic inflammatory demyelinating polyradiculoneuropathy
117. Motor neuropathy with proximal multifocal persistent conduction block, fasciculations and myokymia. Evolution to tetraplegia
118. The spectrum of chronic inflammatory demyelinating polyneuropathy
119. Interferon-alpha may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy
120. The spectrum of neurologic disease associated with anti-GM1 antibodies
121. Multifocal acquired demyelinating sensory and motor neuropathy: The Lewis-Sumner syndrome
122. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: Comparison of patients without and with monoclonal gammopathy
123. Acquired demyelinating polyneuropathy presenting as a pure clinical sensory syndrome
124. Comparison of IgM-MGUS and IgG-MGUS polyneuropathy
125. The natural history of chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. A clinical and neurophysiological study
126. Peripheral neuropathy associated with plasma cell dyscrasia: A clinical and electrophysiological follow-up study
127. Chronic inflammatory demyelinating polyneuropathy (CIDP) in diabetics
128. Polyneuropathy associated with monoclonal gammopathy of undetermined significance: Further evidence that IgM-MGUS neuropathies are different than IgG-MGUS
129. Immunosuppressive treatment of motor neuron syndromes. Attempts to distinguish a treatable disorder
130. The sensitivity and specificity of anti-GM1 antibody testing
131. Chronic inflammatory demyelinating polyneuropathy complicating liver transplantation
132. Focal upper limb demyelinating neuropathy
133. Motor conduction parameters in neuropathies associated with anti-MAG antibodies and other types of demyelinating and axonal neuropathies
134. Minimal and asymptomatic chronic inflammatory demyelinating polyneuropathy
135. Chronic progressive steroid responsive axonal polyneuropathy: A CIDP variant or a primary axonal disorder?
136. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: A double blind, placebo controlled study
137. Treatment of multifocal motor neuropathy with interferon beta-1A
138. Multifocal inflammatory demyelinating neuropathy
139. Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: A meta-analysis
140. Electrophysiologic abnormalities other than conduction block in multifocal motor neuropathy
141. Successful treatment of IgM paraproteinaemic neuropathy with fludarabine
142. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings